Skip to main content
Top
Published in: BMC Women's Health 1/2021

Open Access 01-12-2021 | Research article

Recurrence characteristics and clinicopathological results of borderline ovarian tumors

Authors: Lina Niu, Huihui Tian, Yongjun Xu, Jieqiong Cao, Xu Zhang, Junli Zhang, Jiajia Hou, Weiqin Lv, Junxia Wang, Li Xin, XuFeng Dong, Tao Xu, Yuan Nan, Hua Wei, Xinting Chai, Na Li, Yan Ni, Yun Shang, Lizhen Zhang, Ye Zhao

Published in: BMC Women's Health | Issue 1/2021

Login to get access

Abstract

Background

This study aimed to investigate the clinical and pathological characteristics, and the recurrence and prognostic factors of borderline ovarian tumors (BOTs).

Methods

The data of 286 patients admitted to hospital and followed up for more than ten months were analyzed retrospectively to study the clinicopathological characteristics and related factors of recurrence.

Results

The median age of the patients was 42.06 ± 14.97 years, and the duration of the follow-up ranged from 10–109 months. During the follow-up period, 40 patients had a recurrence. Of these patients, 36 were ≤ 40 years, and patients with premenopausal recurrence accounted for 20.5% (36/176). In patients undergoing conservative treatment or radical operations, the recurrence rates were 21.3% and 1.8%, respectively, and they were 13.4% (36/268) in patients at Federation International of Gynecology and Obstetrics (FIGO) stage I, and 22.2% (4/18) in patients at an advanced stage. Postoperative pathology revealed that 40 patients had micropapillary tumors, among whom ten patients (25%) had a recurrence, and 19 patients had complications with interstitial infiltration. Of these 19 patients, six had a recurrence (31.5%). Another 22 patients had complications with calcified sand bodies; among these, eight patients (36.4%) had a recurrence. All the differences were statistically significant (P < 0.05). There were four cancer-related deaths during the follow-up period. Late FIGO stage, conservative operation, and a high level of carbohydrate antigen 125 (CA125) were independent risk factors for the recurrence of BOTs.

Conclusion

BOTs usually occur in women under 40 years, have an occult onset, and half of the patients have no obvious clinical manifestations. Serum CA125 level can be used as a tumor marker to detect BOTs and the risk of its recurrence. Operation mode and FIGO stage are important independent factors for the recurrence of BOTs.
Literature
1.
go back to reference Kim SH. Assessment of solid components of borderline ovarian tumor and stage I carcinoma: added value of combined diffusion- and perfusion-weighted magnetic resonance imaging. Yeungnam Univ J Med. 2019;36(3):231–40.CrossRef Kim SH. Assessment of solid components of borderline ovarian tumor and stage I carcinoma: added value of combined diffusion- and perfusion-weighted magnetic resonance imaging. Yeungnam Univ J Med. 2019;36(3):231–40.CrossRef
2.
go back to reference Elsherif S, Javadi S, Viswanathan C, Faria S, Bhosale P. Low-grade epithelial ovarian cancer: what a radiologist should know. Br J Radiol. 2019;92(1095):20180571.CrossRef Elsherif S, Javadi S, Viswanathan C, Faria S, Bhosale P. Low-grade epithelial ovarian cancer: what a radiologist should know. Br J Radiol. 2019;92(1095):20180571.CrossRef
3.
go back to reference Guillaume A, Pirrello O. Preservation of fertility in surgery of benign and borderline malignant ovarian tumors. J Visc Surg. 2018;155(S1):S17–21.CrossRef Guillaume A, Pirrello O. Preservation of fertility in surgery of benign and borderline malignant ovarian tumors. J Visc Surg. 2018;155(S1):S17–21.CrossRef
4.
go back to reference Fei-Chi Analysis of prognostic factors in patients with ovarian borderline tumor. Jilin University 2020. Fei-Chi Analysis of prognostic factors in patients with ovarian borderline tumor. Jilin University 2020.
5.
go back to reference Sozen H, Vatansever D, Topuz S, Iyibozkurt C, Kandemir H, Yalçin I, et al. Clinicopathological analysis of borderline ovarian tumours and risk factors related to recurrence: experience of single institution. J Obstet Gynaecol. 2018;39:253–8.CrossRef Sozen H, Vatansever D, Topuz S, Iyibozkurt C, Kandemir H, Yalçin I, et al. Clinicopathological analysis of borderline ovarian tumours and risk factors related to recurrence: experience of single institution. J Obstet Gynaecol. 2018;39:253–8.CrossRef
6.
go back to reference Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(5):672–705.CrossRef Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(5):672–705.CrossRef
7.
go back to reference Zhang Q. Clinical analysis of 240 cases of ovarian borderline tumor. Jinan: ShangDong University; 2019. Zhang Q. Clinical analysis of 240 cases of ovarian borderline tumor. Jinan: ShangDong University; 2019.
8.
go back to reference Vasudevan G, Jaiprakash P, Guruvare S, Samanta N. Ovarian borderline mucinous tumor with squamous overgrowth: an unusual finding with review of literature. Indian J Pathol Microbiol. 2018;61(2):261–3.CrossRef Vasudevan G, Jaiprakash P, Guruvare S, Samanta N. Ovarian borderline mucinous tumor with squamous overgrowth: an unusual finding with review of literature. Indian J Pathol Microbiol. 2018;61(2):261–3.CrossRef
9.
go back to reference Malpica A, Longacre TA. Prognostic indicators in ovarian serous borderline tumours. Pathology. 2018;50(2):205–13.CrossRef Malpica A, Longacre TA. Prognostic indicators in ovarian serous borderline tumours. Pathology. 2018;50(2):205–13.CrossRef
11.
go back to reference Wang W, Zhuang Y, Zhou F, Huang L. Ovarian mucinous borderline tumor accompanied by LGESS with myxoid change: a case report and literature review. Eur J Med Res. 2017;22(1):52.CrossRef Wang W, Zhuang Y, Zhou F, Huang L. Ovarian mucinous borderline tumor accompanied by LGESS with myxoid change: a case report and literature review. Eur J Med Res. 2017;22(1):52.CrossRef
12.
go back to reference Chew KT, Abu MA, Arifuddin Y, Mohamed Ismail NA, Nasir NAM, Mohammed F, Nur Azurah AG. Ectopic adrenal tissue associated with borderline mucinous cystadenoma of ovary: a case report with review of the literature. Horm Mol Biol Clin Investig. 2017. https://doi.org/10.1515/hmbci-2017-0021. Chew KT, Abu MA, Arifuddin Y, Mohamed Ismail NA, Nasir NAM, Mohammed F, Nur Azurah AG. Ectopic adrenal tissue associated with borderline mucinous cystadenoma of ovary: a case report with review of the literature. Horm Mol Biol Clin Investig. 2017. https://​doi.​org/​10.​1515/​hmbci-2017-0021.
13.
go back to reference Sozen H, Vatansever D, Topuz S, Iyibozkurt C, Kandemir H, Yalçin I, et al. Clinicopathological analysis of borderline ovarian tumours and risk factors related to recurrence: experience of single institution. J Obstet Gynaecol. 2019;39:253–8.CrossRef Sozen H, Vatansever D, Topuz S, Iyibozkurt C, Kandemir H, Yalçin I, et al. Clinicopathological analysis of borderline ovarian tumours and risk factors related to recurrence: experience of single institution. J Obstet Gynaecol. 2019;39:253–8.CrossRef
14.
go back to reference Lewis GD, Xing Y, Haque W, Patel T, Schwartz M, Chen A, et al. Prognosis of lymphotropic invasive micropapillary breast carcinoma analyzed by using data from the National Cancer Database. Cancer Commun (Lond). 2019;39(1):60.CrossRef Lewis GD, Xing Y, Haque W, Patel T, Schwartz M, Chen A, et al. Prognosis of lymphotropic invasive micropapillary breast carcinoma analyzed by using data from the National Cancer Database. Cancer Commun (Lond). 2019;39(1):60.CrossRef
15.
go back to reference Yamaguchi S, Aoki T, Ueno M, Fujisaki A, Kawanami T, Yatera K, et al. Micropapillary lung adenocarcinoma showing a diffusely consolidated appearance like lobar pneumonia. J Thorac Imaging. 2019;34(6):W141–3.CrossRef Yamaguchi S, Aoki T, Ueno M, Fujisaki A, Kawanami T, Yatera K, et al. Micropapillary lung adenocarcinoma showing a diffusely consolidated appearance like lobar pneumonia. J Thorac Imaging. 2019;34(6):W141–3.CrossRef
16.
go back to reference Kopkova A, Sana J, Machackova T, Vecera M, Radova L, Trachtova K, et al. Cerebrospinal fluid MicroRNA signatures as diagnostic biomarkers in brain tumors. Cancers (Basel). 2019;11(10):1546.CrossRef Kopkova A, Sana J, Machackova T, Vecera M, Radova L, Trachtova K, et al. Cerebrospinal fluid MicroRNA signatures as diagnostic biomarkers in brain tumors. Cancers (Basel). 2019;11(10):1546.CrossRef
17.
go back to reference Childress KJ, Patil NM, Muscal JA, Dietrich JE, Venkatramani R. Borderline ovarian tumor in the pediatric and adolescent population: a case series and literature review. J Pediatr Adolesc Gynecol. 2018;31(1):48–54.CrossRef Childress KJ, Patil NM, Muscal JA, Dietrich JE, Venkatramani R. Borderline ovarian tumor in the pediatric and adolescent population: a case series and literature review. J Pediatr Adolesc Gynecol. 2018;31(1):48–54.CrossRef
18.
go back to reference Li X, Dai D, Chen B, He S, Zhang J, Wen C, et al. Prognostic values of preoperative serum CEA and CA125 levels and nomograms for young breast cancer patients. Onco Targets Ther. 2019;12:8789–800.CrossRef Li X, Dai D, Chen B, He S, Zhang J, Wen C, et al. Prognostic values of preoperative serum CEA and CA125 levels and nomograms for young breast cancer patients. Onco Targets Ther. 2019;12:8789–800.CrossRef
Metadata
Title
Recurrence characteristics and clinicopathological results of borderline ovarian tumors
Authors
Lina Niu
Huihui Tian
Yongjun Xu
Jieqiong Cao
Xu Zhang
Junli Zhang
Jiajia Hou
Weiqin Lv
Junxia Wang
Li Xin
XuFeng Dong
Tao Xu
Yuan Nan
Hua Wei
Xinting Chai
Na Li
Yan Ni
Yun Shang
Lizhen Zhang
Ye Zhao
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Women's Health / Issue 1/2021
Electronic ISSN: 1472-6874
DOI
https://doi.org/10.1186/s12905-021-01263-y

Other articles of this Issue 1/2021

BMC Women's Health 1/2021 Go to the issue